PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors

Madeline B. Searcy, Randolph K. Larsen, Bradley T. Stevens, Yang Zhang, Hongjian Jin, Catherine J. Drummond, Casey G. Langdon, Katherine E. Gadek, Kyna Vuong, Kristin B. Reed, Matthew R. Garcia, Beisi Xu, Darden W. Kimbrough, Grace E. Adkins, Nadhir Djekidel, Shaina N. Porter, Patrick A. Schreiner, Shondra M. Pruett-Miller, Brian J. Abraham, Jerold E. Rehg and Mark E. Hatley ()
Additional contact information
Madeline B. Searcy: St. Jude Children’s Research Hospital
Randolph K. Larsen: St. Jude Children’s Research Hospital
Bradley T. Stevens: St. Jude Children’s Research Hospital
Yang Zhang: St. Jude Children’s Research Hospital
Hongjian Jin: St. Jude Children’s Research Hospital
Catherine J. Drummond: St. Jude Children’s Research Hospital
Casey G. Langdon: St. Jude Children’s Research Hospital
Katherine E. Gadek: St. Jude Children’s Research Hospital
Kyna Vuong: St. Jude Children’s Research Hospital
Kristin B. Reed: St. Jude Children’s Research Hospital
Matthew R. Garcia: St. Jude Children’s Research Hospital
Beisi Xu: St. Jude Children’s Research Hospital
Darden W. Kimbrough: St. Jude Children’s Research Hospital
Grace E. Adkins: St. Jude Children’s Research Hospital
Nadhir Djekidel: St. Jude Children’s Research Hospital
Shaina N. Porter: St. Jude Children’s Research Hospital
Patrick A. Schreiner: St. Jude Children’s Research Hospital
Shondra M. Pruett-Miller: St. Jude Children’s Research Hospital
Brian J. Abraham: St. Jude Children’s Research Hospital
Jerold E. Rehg: St. Jude Children’s Research Hospital
Mark E. Hatley: St. Jude Children’s Research Hospital

Nature Communications, 2023, vol. 14, issue 1, 1-23

Abstract: Abstract Fusion-positive rhabdomyosarcoma (FP-RMS) driven by the expression of the PAX3-FOXO1 (P3F) fusion oncoprotein is an aggressive subtype of pediatric rhabdomyosarcoma. FP-RMS histologically resembles developing muscle yet occurs throughout the body in areas devoid of skeletal muscle highlighting that FP-RMS is not derived from an exclusively myogenic cell of origin. Here we demonstrate that P3F reprograms mouse and human endothelial progenitors to FP-RMS. We show that P3F expression in aP2-Cre expressing cells reprograms endothelial progenitors to functional myogenic stem cells capable of regenerating injured muscle fibers. Further, we describe a FP-RMS mouse model driven by P3F expression and Cdkn2a loss in endothelial cells. Additionally, we show that P3F expression in TP53-null human iPSCs blocks endothelial-directed differentiation and guides cells to become myogenic cells that form FP-RMS tumors in immunocompromised mice. Together these findings demonstrate that FP-RMS can originate from aberrant development of non-myogenic cells driven by P3F.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-43044-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-43044-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-43044-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().